Dupilumab treatment of eosinophilic gastrointestinal disease in an adolescent
Pediatr Allergy Immunol
.
2023 Jun;34(6):e13973.
doi: 10.1111/pai.13973.
Authors
Francesca Mori
1
,
Sara Renzo
2
,
Simona Barni
1
,
Luca Scarallo
2
3
,
Mattia Giovannini
1
4
,
Vincenzo Villanacci
5
,
Paolo Lionetti
2
3
Affiliations
1
Allergy Unit, Meyer Children's Hospital, IRCCS, Florence, Italy.
2
Gastroenterology and Nutrition Unit, Meyer Children's Hospital, IRCCS, Florence, Italy.
3
Department of NEUROFARBA, University of Florence, Florence, Italy.
4
Department of Health Sciences, University of Florence, Florence, Italy.
5
Institute of Pathology ASST-Spedali Civili, Brescia, Italy.
PMID:
37366213
DOI:
10.1111/pai.13973
No abstract available
Publication types
Letter
MeSH terms
Adolescent
Antibodies, Monoclonal, Humanized / therapeutic use
Enteritis* / drug therapy
Eosinophilia* / drug therapy
Gastritis
Humans
Substances
dupilumab
Antibodies, Monoclonal, Humanized
Supplementary concepts
Eosinophilic enteropathy